Literature DB >> 10631687

Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology.

B S Teh1, S Y Woo, E B Butler.   

Abstract

Intensity modulated radiation therapy (IMRT) is a new technology in radiation oncology that delivers radiation more precisely to the tumor while relatively sparing the surrounding normal tissues. It also introduces new concepts of inverse planning and computer-controlled radiation deposition and normal tissue avoidance in contrast to the conventional trial-and-error approach. IMRT has wide application in most aspects of radiation oncology because of its ability to create multiple targets and multiple avoidance structures, to treat different targets simultaneously to different doses as well as to weight targets and avoidance structures according to their importance. By delivering radiation with greater precision, IMRT has been shown to minimize acute treatment-related morbidity, making dose escalation feasible which may ultimately improve local tumor control. IMRT has also introduced a new accelerated fractionation scheme known as SMART (simultaneous modulated accelerated radiation therapy) boost. By shortening the overall treatment time, SMART boost has the potential of improving tumor control in addition to offering patient convenience and cost savings.

Entities:  

Mesh:

Year:  1999        PMID: 10631687

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  25 in total

1.  Impact of double-balloon rectal catheter use in external-beam radiotherapy for prostate cancer.

Authors:  Kenji Takayama; Takashi Mizowaki; Yoshiharu Negoro; Yoshiki Norihisa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2010-10-05       Impact factor: 3.402

2.  [Constraint priority list-based multi-objective optimization for intensity-modulated radiation therapy].

Authors:  Yan-Hua Mai; Fan-Tu Kong; Yi-Wei Yang; Yong-Bao Li; Ting Song; Ling-Hong Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-06-20

3.  Comparative treatment planning study on sequential vs. simultaneous integrated boost in head and neck cancer patients: Differences in dose distributions and potential implications for clinical practice.

Authors:  Carmen Stromberger; Pirus Ghadjar; Simone Marnitz; Alexander Henry Thieme; Ulrich Jahn; Jan D Raguse; Evis Karaj-Rossbacher; Arne Böttcher; Basil Jamil; Volker Budach
Journal:  Strahlenther Onkol       Date:  2016-01       Impact factor: 3.621

Review 4.  Radiotherapy-Specific Chronic Pain Syndromes in the Cancer Population: An Evidence-Based Narrative Review.

Authors:  Jay Karri; Laura Lachman; Alex Hanania; Anuj Marathe; Mani Singh; Nicholas Zacharias; Vwaire Orhurhu; Amitabh Gulati; Alaa Abd-Elsayed
Journal:  Adv Ther       Date:  2021-02-11       Impact factor: 3.845

5.  Unilateral and bilateral neck SIB for head and neck cancer patients : Intensity-modulated proton therapy, tomotherapy, and RapidArc.

Authors:  Carmen Stromberger; Luca Cozzi; Volker Budach; Antonella Fogliata; Pirus Ghadjar; Waldemar Wlodarczyk; Basil Jamil; Jan D Raguse; Arne Böttcher; Simone Marnitz
Journal:  Strahlenther Onkol       Date:  2016-02-06       Impact factor: 3.621

6.  A case of cervical multicentric Castleman disease treated with intensity-modulated radiation therapy using helical tomotherapy.

Authors:  Natsuo Tomita; Takeshi Kodaira; Takuya Tomoda; Kosei Nakajima; Takayuki Murao; Kunio Kitamura
Journal:  Jpn J Radiol       Date:  2012-01-19       Impact factor: 2.374

Review 7.  Surgical management of retroperitoneal and pelvic sarcomas.

Authors:  Marcus C B Tan; Sam S Yoon
Journal:  J Surg Oncol       Date:  2014-12-05       Impact factor: 3.454

8.  T1-T2 NO oropharyngeal cancers treated with surgery alone. A GETTEC study.

Authors:  Alain Cosmidis; Jean-Pierre Rame; Olivier Dassonville; Stéphane Temam; François Massip; Gilles Poissonnet; Marc Poupart; Patrick Marandas; Dominique De Raucourt
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-10-09       Impact factor: 2.503

9.  Analysis of factors influencing the development of xerostomia during intensity-modulated radiotherapy.

Authors:  Ken Randall; Jason Stevens; Juan Fernando Yepes; Marcus E Randall; Mahesh Kudrimoti; Jonathan Feddock; Jing Xi; Richard J Kryscio; Craig S Miller
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-03-22

10.  Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma.

Authors:  Dong Wook Kim; Kwangzoo Chung; Weon Kuu Chung; Sun Hyun Bae; Dong Oh Shin; Seongeon Hong; Sung Ho Park; Sung-Yong Park; Chae-Seon Hong; Young Kyung Lim; Dongho Shin; Se Byeong Lee; Hyun-ho Lee; Jiwon Sung; Myonggeun Yoon
Journal:  Radiat Oncol       Date:  2014-05-08       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.